KYTX · Kyverna Therapeutics, Inc.
$8.61
-0.23 (-2.60%)
At close · Aug 26
Market Cap
$544.22M
Shares
61.84M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$8.61
Open$8.81
Day$8.50–8.84
52W close$3.59–11.25
Avg vol 30d803K
Short int8.5M · 13.7% float · 13.3d
Short vol47%
Last earningsMay 12, 2026
DataFeb 2024–Aug 2026
Filing10-Q · Aug 11
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 11, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Neutral
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.2 · calm
Equity put/call 0.64
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+3%
above
Price vs 50-day avg
+6%
above
RSI (14)
55
neutral
MACD trend
Positive
52-week position
66%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+22%
trailing
6-month return
+3%
trailing
YTD return
−8%
this year
Relative strength
−10%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $8 › 200d $8 — 200d above 50d
Institutional flow
Accumulating
+6% holders QoQ · +30 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
13.74% of float · ▲ +3.9% MoM · 13.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
119 holders — near 2-yr high, broad support
Squeeze score
67
elevated · 0–100
Fundamentals
EPS growth
−9%
Y/Y
Free cash flow
$-153.7M
Balance sheet
$99.4M
net cash
Quant / Vol
risk profile
Volatility
101%
annualized · 1-yr
Max drawdown
−37%
past year
ATR
6.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+3%
Bullish
Price vs 50-day avg
+6%
Bullish
RSI (14)
55
Neutral
MACD trend
Positive
Bullish
52-week position
66%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $8 › 200d $8 — 200d above 50d
Institutional flow
Accumulating
+6% holders QoQ · +30 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
13.74% of float · ▲ +3.9% MoM · 13.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
119 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $4
Now $9 · 66%
Range high $11
vs 200-day avg +3%
vs 50-day avg +6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KYTX
this stock
Kyverna Therapeutics, Inc.
|
$544.22M | -8.4% | — | — | 13.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.72B | +20.7% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.89B | +5.6% | +20.8% | 20.2 | 2.3% |
|
ARGX
Argenx SE
|
$63.81B | +24.5% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$60.07B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KYTX | -2.9% | +21.8% | +2.6% | +18.0% | -8.4% |
| SPY | -0.4% | +5.0% | +12.4% | +2.6% | +12.3% |
| vs SPY | -2.5% | +16.8% | -9.8% | +15.4% | -20.7% |
Key facts
CIK
1994702
CUSIP
501976104
13F (30d)
108 filings
107 filers
Visit website
Investor relations